Pages
- About us
- AQCAMO
- Become a member of AQCAMO
- Conferences and partner capsules
- Congress 2024 Photos
- Contact us
- Events
- Frequently asked questions
- Insurance companies
- Member dashboard
- News
- No access
- Partners
- Privacy policy
- Reimbursement
- Role of the Drug Access Navigators CAMs-DANs
- Rx list
- Site map
- Support
- Terms and conditions of use
- Useful links
- Webinars
Posts by category
- Category: Events
- Category: News
- VANFLYTA (quizartinib)
- Osimertinib(Tagrisso)
- PrKEYTRUDA® (pembrolizumab)
- Truqap (capivasertib)
- ZOLADEX® LA (10.8 mg) in breast cancer
- Scemblix® (asciminib)
- Scemblix® (asciminib)
- PrKEYTRUDA® (pembrolizumab)
- NUBEQA (darolutamide)
- OPDIVO® + YERVOY® New Patient Support Programs from Bristol Myers Squibb Canada
- Durvalumab (Imfinzi): Muscle-invasive bladder cancer (MIBC)
- KEYTRUDA® (Pembrolizumab)
- LAZCLUZE® (Lazertinib)
- AstraZeneca Canada will discontinue the free drug access component of the PSP for all NEW patients enrolled after March 31, 2025.
- Durvalumab (Imfinzi)
- Enhertu (Trastuzumab Deruxtecan)
- Pembrolizumab (Keytruda) New indication
- Category: Non catégorisé
